
Rottapharm Biotech: POC in osteoarthritis pain
Results of the proof-of-concept trial suggest the selective imidazoline-2 (I2) receptor agonist CR4056 could be an alternative to the...

GHO capital launches EU's largest fund ever for life sciences
Global Healthcare Opportunities, or GHO Capital Partners LLP said that its finally closed Fund II will be focussed on high growth healthcare...

Magenta Therapeutics exercises ATAC licence option
Stem cell specialist Magenta Therapeutics (Cambridge, MA, USA) agreed to pay up to $85m in milestones for the rights to exclusively develop and...

Versantis raises CHF16m in Series B financing
The CHF16m Series B financing was led by Swisscanto Invest by Zürcher Kantonalbank with co-financing by Esperante Venture, investiere, Redalpine...

ADC Therapeutics enters licence option deal with Avacta Group
Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to undisclosed cancer...

NSCLC: Bemcentinib + anti-PD1 triple PFS
Bergen Bio ASA announced the primary endpoint of 25% Overall Response Rate (ORR) has been met in predominantly PD-L1 negative/low NSCLC patients in a...

Successful EFIB in Brussels
More than 260 companies with 480 delegates from 30 countries joined for this year’s “European Forum for industrial Biotechnology and Bioeconomy”...